How does cladribine work in MS
Lead researcher: Dr Klaus Schmierer
Based in: Queen Mary, University of London
Grant we awarded: £33,960
Researchers believe that cladribine could also be an effective treatment for progressive MS, and want to run a large trial. To corroborate the trial they want to understand how the treatment works in more detail.
What will happen in the project?
Cladribine kills certain immune cells called B and T cells, which we know are important in inflammation and myelin damage in MS. Our researchers believe that a key part of cladribine’s potential is its ability to target a specific type of mature B cell, both in the blood and the central nervous system.
They will test this theory by looking for changes in the levels of immune cells, their products and certain biomarkers in people who have had cladribine injections. These will be measured in people’s blood and the fluid surrounding their brain and spinal cord.